The Swedish national air navigation service provider, LFV, has
contracted with Naverus, Inc., to perform an analysis of the country’s
airspace. The analysis will develop strategies for reducing aircraft
exhaust emissions, noise and delays […]
Celgene International Sàrl(NASDAQ: CELG) announced that
data from a landmark analysis of patients with relapsed/refractory
multiple myeloma found that continuous treatment with REVLIMID
(lenalidomide) in combination with dexamethasone after achieving best
response resulted in significantly […]
Celgene International Sàrl (Nasdaq: CELG) today announced that its next
IMiDs compound, pomalidomide, has shown promising activity with
manageable safety and tolerability for the treatment of
relapsed/refractory multiple myeloma (MM) and myelofibrosis. The data
[…]
Amazon Web Services LLC (AWS), subsidiary of Amazon.com, Inc., (NASDAQ:
AMZN), today announced that it has extended Amazon Elastic Compute Cloud
(Amazon EC2) to Europe. European developers and businesses can now run
their Amazon […]
Sonoco (NYSE: SON), one of the largest diversified global packaging
companies, has been awarded a contract by Colgate-Palmolive to manage
all European promotional packing requirements for Colgate’s oral care
products. Sonoco’s pack center will […]
Celgene International Sàrl (Nasdaq:CELG) today announced more mature
data from clinical studies of REVLIMID (lenalidomide) in newly-diagnosed
multiple myeloma were presented at a joint symposium of the American
Society of Clinical Oncology (ASCO) and […]
Chi-X® Europe Limited, operator of the largest pan-European
equity multilateral trading facility (MTF), and Intelligent Financial
Systems Limited (IFS), providers of historical data and trading
applications to the financial markets, today announced the introduction
[…]
Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to
treat gastrointestinal disorders and diseases, announced today the
completion of the Phase I clinical trial of SP-304 in healthy volunteers
that was initiated […]
Celgene International Sàrl (NASDAQ: CELG) reported that results
of a Phase I study presented today combining REVLIMID and VIDAZA in
patients with higher-risk myelodysplastic syndromes (MDS) found that the
combination of these two therapies […]
Celgene International Sàrl (NASDAQ: CELG) today announced results from a
subset analysis of the international phase III trial (AZA-001)
demonstrating that the overall survival benefit observed in higher-risk
MDS patients extends to patients with […]